Hints and tips:
...Many are medtech or biotech companies, including Decibel Therapeutics and Fulcrum Therapeutics. Google dissolved healthcare unit Google Health in 2021....
...That day she told the firm’s human resources department about her medical condition and a therapeutic need to get eight to nine hours of sleep a night, later confirmed by a nurse’s note....
...Monday’s acquisition by Novartis of Seattle-based biotech firm Chinook Therapeutics for up to $3.5bn is a case in point....
...Its flagship fund, the Innovation ETF, which is dominated by holdings in electric car maker Tesla, streaming company Roku and biotech Crispr Therapeutics, appreciated by 150 per cent last year....
...She is also a cheerleader for this emerging field of medical science, telling CNBC in December that three listed companies in the space — Intellia, Crispr Therapeutics and Editas — represent a “trillion...
...Zhao declined to comment. 12) Telis Bioscience ($1mn for 2pc) CEO Grigory Khimulya says Telis Bioscience is “a venture-backed biotech company in Cambridge, MA engineering high-impact protein therapeutics...
...Meanwhile, US start-up Intellia Therapeutics has successfully treated the first patients using a Crispr gene-editing therapy directed inside the body to an internal organ — a breakthrough, with the technology...
...The Celgene takeover is the largest of several significant pharma and healthcare deals in the first quarter, with others including Roche’s $4.8bn purchase of gene therapy company Spark Therapeutics and Johnson...
...For one, shares in Menlo Therapeutics, a pharmaceutical company making treatments for itchy skin and coughs, are down 53 per cent from their offer price after its drug serlopitant underperformed in one of...
...In one quirk, a move by S&P Dow Jones Indices to promote biotech company Nektar Therapeutics from the S&P 600 to the S&P 500 in mid-March has also had an effect on the indices’ relative performance....
...Shield Therapeutics’ prospects were supposed to be pretty much iron clad. But the Aim-quoted biopharma business developing treatments for anaemia couldn’t shield investors last week....
...Corporate earnings and updates for Wednesday include Kingfisher, Cambian Group, Cenkos Securities and Shield Therapeutics....
...His world-class experience in immunology, oncology and translational medicine will be vital assets as Sanofi sets its sights on scientific excellence and innovation across its therapeutic areas....
...At this stage of a new drug’s life there’s presumed to be no evidence that it has any therapeutic value whatsoever. Nevertheless, KaloBios is now valued at circa $150m....
...Intellia Therapeutics raised $15m last year before signing a collaboration with Novartis in January....
...The move was the third-largest opening “pop” this year behind the debuts of Shake Shack and Spark Therapeutics, according to Dealogic....
..., which claims to have built the world’s biggest database of human genetic data through its $99 DNA saliva test, said that Richard Scheller would join as chief science officer to lead the company’s new therapeutics...
...Health: The Amazon founder has participated in two fundraising rounds in Juno Therapeutics, a company which is developing immunotherapies for the treatment of cancer....
...“The fibrosis benefit with OCA treatment is the first time we are aware of that a therapeutic has been shown to significantly improve liver fibrosis in a meaningful proportion of NASH patients, an unexpected...
...It will also pay $20m to take an equity stake in ADC Therapeutics, a Swiss based cancer drug developer....
...I find different types of exercise, usually outside, very therapeutic. And reading – especially about China....
...The company also plans to spend up to $78m for an 18 per cent stake in Speranza Therapeutics, a spin-off company with an experimental drug for Alzheimer’s disease, while issuing new debt for $800m....
...The deal that will give Rusnano a minority stake in Coda Therapeutics has obvious benefits for Domain, drawing a heavyweight Russian investor into one of its existing portfolio companies....
...SAC’s bets on stocks including United Therapeutics Corp, Genentech Inc. and ViroPharma Inc attracted Finra’s attention because they were made before market-moving events, such as acquisitions and the release...
...Karen Bechtel, managing director and head of Carlyle’s healthcare group, said the buy-out firm would help to expand PPD’s therapeutic expertise....
International Edition